- Conditions
- Bipolar Disorder, Cocaine Dependence, Methamphetamine Dependence
- Interventions
- quetiapine, risperidone
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 52
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Risperidone, Olanzapine, Quetiapine, Aripiprazole
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 28
- States / cities
- Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
- Conditions
- Apathy, Schizophrenia, Schizophrenia; Psychosis
- Interventions
- Lumateperone 42 mg, Risperidone 2 mg
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Alzheimer's Disease
- Interventions
- Olanzapine, Quetiapine, Risperidone, Citalopram
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 34
- States / cities
- Tuscaloosa, Alabama • Irvine, California • Los Angeles, California + 29 more
- Conditions
- Schizophrenia
- Interventions
- perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 54
- States / cities
- Chula Vista, California • Los Angeles, California • Orange, California + 45 more
- Conditions
- Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
- Interventions
- risperidone, quetiapine, olanzapine, divalproex
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
- Interventions
- Ziprasidone, aripiprazole, quetiapine, or risperidone
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia
- Interventions
- LY2140023, Placebo, Standard of Care
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
- Conditions
- Psychotic Disorders
- Interventions
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 8 Years to 19 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina
- Conditions
- Bipolar Disorder
- Interventions
- Lithium Carbonate, Optimized Treatment (OPT)
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 6
- States / cities
- Stanford, California • Boston, Massachusetts • Cleveland, Ohio + 3 more
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
- Drug
- Lead sponsor
- Matt Byerly
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Schizophrenia and Schizoaffective Disorder
- Interventions
- Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- quetiapine fumarate, risperidone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,098 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 63
- States / cities
- Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more
- Conditions
- Bipolar I Disorder
- Interventions
- Injectable Risperidone (Consta) or oral antipsychotic
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 4
- States / cities
- Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more
- Conditions
- Schizophrenia
- Interventions
- quetiapine fumarate vs risperidone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
- Interventions
- risperidone, olanzapine, quetiapine, ziprasidone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 2
- States / cities
- St Louis, Missouri
- Conditions
- Treatment-resistant Schizophrenia
- Interventions
- Clozapine, Antipsychotics,Other (non-Clozapine)
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Bipolar Disorder
- Interventions
- Ketogenic foodstuffs, Standard of Care Oral antipsychotics, Standard of care long acting injectable medication for bipolar disorder
- Dietary Supplement · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Montgomery, Alabama
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Abuse, Substance Dependence
- Interventions
- Quetiapine, Risperidone
- Drug
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
- Interventions
- Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 6
- States / cities
- Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
- Conditions
- Schizophrenia
- Interventions
- AVE1625, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Schizophrenia
- Interventions
- MK-8189, Placebo, Background AAP Therapy
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Schizophrenia
- Interventions
- Risperidone, Olanzapine, Quetiapine
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 21 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- risperidone, quetiapine
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 7
- States / cities
- San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more